Latest TechBio News 🌀
Proscia has been named to Fierce Medtech ’s “Fierce 1️⃣5️⃣” list for 2️⃣0️⃣2️⃣5️⃣
On June 3, 2025, Proscia announced its inclusion in Fierce Medtech’s “Fierce 15” of 2025. This annual list honors private companies making an outsized impact on healthcare. Proscia earned its spot for its AI pathology leadership 🎩 across the precision medicine value chain (Fierce Medtech Names AI Pathology Leader Proscia to 2025 Fierce 15). (View the full Fierce 15 list here).
Proscia’s Concentriq® platform delivers a uniquely comprehensive approach to AI from drug discovery to diagnostics. It incorporates a portfolio of best-in-class applications, tools for building algorithms, and AI-native features into routine workflows, helping its user base of over 12,000 pathologists and scientists to drive efficiencies, identify novel biomarkers, and develop and deploy companion diagnostics. Concentriq is trusted by 1️⃣6️⃣ of the top 2️⃣0️⃣ pharmaceutical companies as well as major laboratories set to diagnose 3️⃣2️⃣, 0️⃣ 0️⃣ 0️⃣ patients per day on the platform this year.
💬 “AI in pathology is about much more than use case-specific applications and individual foundation models. We’re equipping both life sciences organizations and diagnostic laboratories to fully harness AI’s potential to rewire pathology and drive precision medicine forward. Fierce Medtech’s recognition validates the impact of our broad approach for our users and patients.”
said David West, Proscia’s CEO.
This honor builds on a series of high-impact milestones for Proscia:
▶️ Last week, Labcorp announced it adopted Concentriq LS to accelerate clinical trials and companion diagnostic development as part of its expanded precision oncology portfolio.
Labcorp says it can now move tumor slides at internet speed instead of parcel speed. One factor that powers them is an enhanced platform tapping Leica Biosystems Aperio GT450 scanners and managed by Proscia’s Concentriq LS image management system. This combination provides scalable, file-agnostic infrastructure, enabling Labcorp to archive and manage high-volume digital slides, facilitate real-time global peer review, and integrate AI-driven image analysis for enhanced diagnostic insights (Labcorp ramps up oncology R&D speed with advanced diagnostics and digital pathology). By centralizing the review, analysis, and AI-driven interpretation on Proscia‘s Concentriq platform, Labcorp is streamlining the development and validation of companion diagnostics for its pharma sponsors.
Moreover, by combining high-throughput tissue NGS, a rapid AML panel, expanded ctDNA liquid biopsy capabilities with Labcorp Plasma Focus now available in Geneva and Shanghai, and real-time digital slide review, Labcorp is positioning itself as a comprehensive partner for accelerating companion diagnostic development and streamlining precision-oncology trial enrollment.
▶️ Proscia also recently launched Concentriq Embeddings to accelerate AI development with foundation models, demonstrating a 1️⃣3️⃣x efficiency gain.
▶️ Additionally, the company introduced a real-world data offering enabling data scientists to leverage over 1️⃣0️⃣ million pathology images with associated clinical and genomic data to fuel their AI algorithms.
▶️ In March 2025, the company announced 💲5️⃣0️⃣M in funding led by Insight Partners, alongside Alpha Intelligence Capital, Triangle Peak Partners, and more. Finally, the company is also adding to the 120+ research and diagnostic applications already available on the platform through its precision medicine AI portfolio.